Plasma exchange and human factor VIII concentrate in managing haemophilia A with factor VIII inhibitors.
Plasma exchanges were combined with human factor VIII concentrate therapy in the treatment of major bleeding episodes in five patients with haemophilia A and factor VIII inhibitors. All patients had a good clinical response to combined treatment. Inhibitor levels showed satisfactory falls before rapid secondary increases of inhibitor levels took place. A sixth patient with von Willebrand's disease and a factor VIII clotting activity inhibitor was successfully prepared for operation using plasma exchange. Postoperative haemostasis and healing were normal. In two patients the plasma exchanges were relatively more effective than the administered human factor VIII in reducing the levels of factor VIII inhibitor. Combined plasma exchange and human factor VIII treatment may offer a rapidly effective means of reducing factor VIII inhibitor levels in this group of patients, together with significant saving of costs.
D005169:Factor VIII / Q000037:antagonists & inhibitors* / Q000627:therapeutic use*; D006467:Hemophilia A / Q000097:blood / Q000628:therapy*; D006801:Humans; D008297:Male; D010951:Plasma Exchange; D014842:von Willebrand Diseases / Q000097:blood / Q000628:therapy
D005169:Factor VIII